Abstract
The tumour agnostic label for larotrectinib and entrectinib as approved by the European Medicines Agency announced a new era of personalized medicine in Europe. This study assessed whether future innovative personalized treatments entering the European market may learn lessons from tumour agnostic products, by exploring and comparing the variety of uncertainty considerations by different stakeholders (clinical trial design, regulators, health technology assessment (HTA), payers and clinical guideline developers) throughout the lifecycle?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
